2. Academic Validation
  3. A Novel CD206 Targeting Peptide Inhibits Bleomycin-Induced Pulmonary Fibrosis in Mice

A Novel CD206 Targeting Peptide Inhibits Bleomycin-Induced Pulmonary Fibrosis in Mice

  • Cells. 2023 Apr 26;12(9):1254. doi: 10.3390/cells12091254.
Anghesom Ghebremedhin 1,  Ahmad Bin Salam 2,  Benjamin Adu-Addai 3,  Steve Noonan 4,  Richard Stratton 5,  Md Shakir Uddin Ahmed 2 6,  Chandra Khantwal 4,  George R Martin 7,  Huixian Lin 2,  Chris Andrews 2,  Balasubramanyam Karanam 2,  Udo Rudloff 8,  Henry Lopez 4,  Jesse Jaynes 9,  Clayton Yates 2
Affiliations

Affiliations

  • 1 Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA.
  • 2 Department of Biology and Center for Cancer Research, Tuskegee University, Carver Research Foundation, Tuskegee, AL 36088, USA.
  • 3 Department of Pathobiology, College of Veterinary Medicine, Tuskegee University, Tuskegee, AL 36088, USA.
  • 4 Murigenics Inc., 941 Railroad Ave., Vallejo, CA 94592, USA.
  • 5 Royal Free Hospital, UCL Division of Medicine, University College London, London WC1E 6JF, UK.
  • 6 Bangladesh Council of Scientific and Industrial Research, Dhaka 1205, Bangladesh.
  • 7 Riptide Bioscience, 941 Railroad Ave., Vallejo, CA 94592, USA.
  • 8 Rare Tumor Initiative, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
  • 9 College of Agriculture, Environment and Nutrition Sciences, Tuskegee University, Tuskegee, AL 36088, USA.
PMID: 37174654 DOI: 10.3390/cells12091254
Abstract

Activated M2-polarized macrophages are drivers of pulmonary fibrosis in several clinical scenarios, including Idiopathic Pulmonary Fibrosis (IPF). In this study, we investigated the effects of targeting the CD206 receptor in M2-like macrophages with a novel synthetic analogue of a naturally occurring Host Defense Peptide (HDP), RP-832c, to decrease profibrotic cytokines. RP-832c selectively binds to CD206 on M2-polarized bone marrow-derived macrophages (BMDM) in vitro, resulting in a time-dependent decrease in CD206 expression and a transient increase in M1-macrophage marker TNF-α. To elucidate the antifibrotic effects of RP-832c, we used a murine model of bleomycin (BLM)-induced early-stage pulmonary fibrosis. RP-832c significantly reduced fibrosis in a dose-dependent manner, and decreased CD206, TGF-β1, and α-SMA expression in mouse lungs. Similarly, in an established model of lung fibrosis, RP-832c significantly decreased lung fibrosis and significantly decreased inflammatory cytokines TNF-α, IL-6, IL-10, IFN-γ, CXCL1/2, and fibrosis markers TGF-β1 and MMP-13. In comparison with the FDA-approved drugs Nintedanib and Pirfenidone, RP-832c exhibited a similar reduction in fibrosis compared to Pirfenidone, and to a greater extent than Nintedanib, with no apparent toxicities observed. In summary, our findings showed that inhibiting the profibrotic alternatively activated M2-like macrophages using a novel peptide, RP-832c, could reduce BLM-induced pulmonary fibrosis in mice, warranting the therapeutic potential of this peptide for patients with pulmonary fibrosis.

Keywords

CD206; IPF; immunotherapy; macrophages; myofibroblasts.

Figures
Products